Mark Kaminski
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment 106
-
- Radiopharmaceutical Chemistry and Applications 42
- Monoclonal and Polyclonal Antibodies Research 30
- Medical Imaging Techniques and Applications 18
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 27
- Oncology top 1%
- Viral-associated cancers and disorders 27
- Hematology top 1%
-
- Lung Cancer Treatments and Mutations 30
-
- Semantic Web and Ontologies 22
Mark Kaminski
186 papers receiving 7.8k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Pathology and Forensic Medicine 4.2k
- Radiology, Nuclear Medicine and Imaging 3.5k
- Genetics 1.3k
- Oncology 2.7k
- Hematology 771
Countries citing papers authored by Mark Kaminski
This map shows the geographic impact of Mark Kaminski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kaminski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kaminski more than expected).
Fields of papers citing papers by Mark Kaminski
This network shows the impact of papers produced by Mark Kaminski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kaminski. The network helps show where Mark Kaminski may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Kaminski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2023 | 6 | |
| 3 | 2021 | 19 | |
| 4 | 2019 | 7 | |
| 5 | The Window Validity Problem in Rule−Based Stream Reasoning | 2018 | 0 |
| 6 | 2017 | 1 | |
| 7 | 2016 | 35 | |
| 8 | 2014 | 27 | |
| 9 | 2013 | 32 | |
| 10 | Sufficient Conditions for First-Order and Datalog Rewritability in ELU. | 2013 | 7 |
| 11 | 2013 | 2 | |
| 12 | 2012 | 123 | |
| 13 | 2012 | 311 | |
| 14 | 2011 | 27 | |
| 15 | 2009 | 132 | |
| 16 | 2008 | 135 | |
| 17 | 2008 | 68 | |
| 18 | Re-treatment with Tositumomab and Iodine I 131 Tositumomab in patients with non-Hodgkin lymphoma who had previously responded to Tositumomab and Iodine I 131 Tositumomab | 2005 | 2 |
| 19 | 1995 | 2 | |
| 20 | 1985 | 105 |
About Mark Kaminski
Mark Kaminski is a scholar working on Pathology and Forensic Medicine, Genetics, Radiology, Nuclear Medicine and Imaging, Oncology and Hematology, having authored 193 papers that have together received 8.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (106 papers), Radiopharmaceutical Chemistry and Applications (42 papers), Monoclonal and Polyclonal Antibodies Research (30 papers), Lung Cancer Treatments and Mutations (30 papers), Chronic Lymphocytic Leukemia Research (27 papers), Viral-associated cancers and disorders (27 papers), Semantic Web and Ontologies (22 papers) and Medical Imaging Techniques and Applications (18 papers). The work is most often cited by research in Pathology and Forensic Medicine (4.2k citations), Radiology, Nuclear Medicine and Imaging (3.5k citations), Genetics (1.3k citations), Oncology (2.7k citations) and Hematology (771 citations). Mark Kaminski has collaborated with scholars based in United States, United Kingdom and Poland. Frequent co-authors include Richard L. Wahl, Kenneth Zasadny, Isaac R. Francis, Denise Regan, Charles W. Ross, Andrew D. Zelenetz, Stewart Kroll, Judith Estes, Susan J. Fisher and Melissa Tuck. Their work appears in journals such as Blood, Journal of Clinical Oncology, The Journal of Immunology, Clinical Cancer Research and Cancer Biotherapy and Radiopharmaceuticals.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.